NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD
1.22
-0.07 (-5.43%)
The current stock price of FBLG is 1.22 USD. In the past month the price increased by 19.61%. In the past year, price decreased by -87.93%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
FIBROBIOLOGICS INC
455 E. Medical Center Blvd, Suite 300
Houston TEXAS US
Employees: 10
Company Website: https://fibrobiologics.com/
Investor Relations: http://ir.fibrobiologics.com/sec-filings/all-sec-filings
Phone: 12816715150
The current stock price of FBLG is 1.22 USD. The price decreased by -5.43% in the last trading session.
The exchange symbol of FIBROBIOLOGICS INC is FBLG and it is listed on the Nasdaq exchange.
FBLG stock is listed on the Nasdaq exchange.
9 analysts have analysed FBLG and the average price target is 10.97 USD. This implies a price increase of 798.77% is expected in the next year compared to the current price of 1.22. Check the FIBROBIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FIBROBIOLOGICS INC (FBLG) has a market capitalization of 46.04M USD. This makes FBLG a Nano Cap stock.
FIBROBIOLOGICS INC (FBLG) currently has 10 employees.
FIBROBIOLOGICS INC (FBLG) has a resistance level at 1.28. Check the full technical report for a detailed analysis of FBLG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FBLG does not pay a dividend.
FIBROBIOLOGICS INC (FBLG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
The outstanding short interest for FIBROBIOLOGICS INC (FBLG) is 7.61% of its float. Check the ownership tab for more information on the FBLG short interest.
ChartMill assigns a technical rating of 3 / 10 to FBLG. When comparing the yearly performance of all stocks, FBLG is a bad performer in the overall market: 95.19% of all stocks are doing better.
Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 49.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -67.87% | ||
ROE | -408.08% | ||
Debt/Equity | 3.35 |
ChartMill assigns a Buy % Consensus number of 82% to FBLG. The Buy consensus is the average rating of analysts ratings from 9 analysts.